Research Reference
Vladonix
Thymus gland peptide bioregulator for immune function
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Preclinical-Only — For Educational Purposes Only
This compound has no established human dosing. The information below documents preclinical (animal) findings and is provided for research and educational reference only. It is not medical advice or a dosing recommendation.
Vladonix is a thymus gland peptide bioregulator studied for immune function in preclinical research. There is no established human dosing.
Reconstitution
Vladonix is a peptide bioregulator complex (thymus-derived) developed in the Russian Federation and registered there. It is supplied as capsules for oral use. It is not FDA-approved in the United States.
No injectable or reconstituted form is established. Compounded "research" forms sold online are not FDA-approved.
Cycling Protocol
Studied CIS-region protocols describe Vladonix taken orally (capsules) daily for 1 month, sometimes repeated after 3–6 months. No standardized long-term cycle is established; Vladonix is not FDA-approved and durations are community extrapolation.
Routes of Administration
No injectable route is established. Vladonix is not FDA-approved in the US.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Immune bioregulator | Vladonix + Vilon / Thymalin | Combined CIS-region immune bioregulators (community) |
Stacking combinations are community extrapolation. Vladonix is not FDA-approved.
Side Effects & Safety
- No human safety database in US frameworks — Vladonix is not FDA-approved and Western safety data is limited
- Generally described as well-tolerated in the published CIS-region literature at studied doses
- Allergic reactions — rare
Vladonix is not FDA-approved in the United States. It is registered in some other countries. Compounded forms are not FDA-approved.
Research Basis
Vladonix is a peptide bioregulator complex derived from thymus tissue, developed in the Russian Federation (St. Petersburg Institute of Bioregulation and Gerontology).
Mechanism: Described as a tissue-specific bioregulator supporting thymus and immune function, in the peptide-bioregulator tradition.
Clinical evidence: Published CIS-region studies describe use in immune support and aging contexts, typically as oral 1-month courses. Not FDA-approved in the US; Western trial data is limited.
Not FDA-approved in the US. Compounded forms are sold for research purposes only.